Lineage Cell The SEC Filings

Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Lineage Cell Therapeutics, Inc. (LCTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. Lineage is incorporated in California and its common stock trades on the NYSE American under the symbol LCTX. Through periodic and current reports, investors can review how the company describes its allogeneic, or “off the shelf,” cell therapy programs, its proprietary pluripotent cell–based platform, and its development and manufacturing activities.

Among the most relevant documents for analysis are Lineage’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically summarize its pipeline, including OpRegen retinal pigment epithelial cell therapy for geographic atrophy secondary to age-related macular degeneration, OPC1 oligodendrocyte progenitor cell therapy for spinal cord injuries, ReSonance (ANP1) for hearing loss, PNC1 for potential treatment of vision loss, the RND1 hypoimmune induced pluripotent stem cell line, and the ILT1 islet cell transplant initiative for Type 1 Diabetes. These filings also discuss the company’s proprietary manufacturing approaches, such as its two-tiered cGMP cell banking system and AlloSCOPE framework.

Current reports on Form 8-K provide timely details on material events, including collaboration agreements, clinical and manufacturing milestones, equity financings, and governance matters. Recent 8-K filings describe, for example, a development milestone payment under the Roche and Genentech collaboration for OpRegen, a research collaboration agreement with William Demant Invest A/S for ReSonance, capital raised through a block transaction under an at-the-market offering program, and updates related to grant applications for the OPC1 program.

On Stock Titan, these filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, helping users quickly identify disclosures related to clinical progress, collaboration economics, equity issuances, and shareholder approvals. Investors can also monitor additional SEC forms, such as proxy materials referenced in 8-K filings, to better understand Lineage’s equity incentive plans and shareholder voting outcomes.